Cash and cash equivalents were $34.6M as of December 31, compared to $31.0M as of September 30 and $36.M as of December 31, 2023. In ...

Surrozen will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its ophthalmology programs including development of new treatment options for retinopathies. Other ...

Surrozen said despite SZN-043 demonstrating changes in liver function assays, there was not enough clinical benefit for ...

Surrozen is discontinuing its sole clinical-stage candidate and pivoting to its preclinical ophthalmology pipeline after the ...

Surrozen (NASDAQ:SRZN) filed a prospectus related to the offer and sale of 1.09M shares of common stock. This preliminary prospectus is not an offer to sell. Filing Surrozen announces up to $192 ...

Surrozen focuses on ophthalmology programs, raising $175 million to advance treatments while discontinuing SZN-043 for alcohol-associated hepatitis. Surrozen, Inc. has announced a strategic shift ...

Surrozen, Inc. (NASDAQ:SRZN – Get Free Report) was down 3.6% during mid-day trading on Monday .The stock traded as low as $11.21 and last traded at $12.00. Approximately 146,213 shares traded ...

Surrozen, Inc. SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that ...

Surrozen is dropping its sole clinical asset after the drug failed at Phase I, as the company considers a move into ophthalmology instead. Development of SZN-043 is being discontinued in severe ...

Surrozen will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its ophthalmology programs including development of new treatment options for retinopathies.

SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (SRZN) (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering ...